Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
Get this delivered to your inbox, and more info about our products and services.
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.
HSBC signals a potential cooling period for the red-hot obesity drug trade.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its…
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing…
